← Human Trials & Peer-Reviewed Studies
Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal aortic aneurysm repair.
Plain-language guide to PMID 9539069 (1998): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 9539069
- Journal
- Intensive care medicine
- Year
- 1998
- Study type
- Randomized Controlled Trial
- Authors
- Mealy K et al. (8 authors)
- DOI
- 10.1007/s001340050533
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
To examine rhGH effects on hepatic acute phase protein responses and inflammatory cytokine release in patients undergoing major surgery.
Who Took Part
By PubMed's age tags, the people studied were older adults, both men and women.
Patients undergoing elective abdominal aortic aneurysm repair.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
Prospective double blind randomised trial.
Tertiary referral university teaching hospital.
What Was Measured
The subject headings attached to it are Aortic Dissection, Aortic Aneurysm, Abdominal, Apolipoproteins, C-Reactive Protein, Critical Illness, Human Growth Hormone and Inflammation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 1998 (Intensive care medicine), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.